November 5, 2018

Share Press Releases Start-ups

T3 BioScience’s product successfully fighting devastating fire blight on apples/pears


T3 BioScience LLC reported that it has obtained independent successful test results from five different US state universities from its 2018 field tests of its non-antibiotic T3 Protect treatment fighting fire blight on apples and pears.

“We are very pleased that this year again, the external field tests have shown excellent results for our T3 Protect product across multiple states reflecting our country’s various climates.” Confirms Dr. Ching-Hong Yang, CSO of T3 BioScience, and continues: “For the second time we have tested a commercial like version of the product, that will be sustainable to nature’s impacts such as UV and rain during apple bloom and that has a shelf-live of two years. Since starting independent external field tests in 2016, results of our product’s efficiency fighting this serious disease on apples and pears have been very consistent. Hence, we stay on track for our objective to create a non-antibiotic, environmentally friendly treatment that should be as efficient as any commercial antibiotic currently available in the market.”

Professor for plant bacteriology at Michigan State University Dr. George Sundin, was one of the 2018 testing state universities since 2016 and explains further: “T3 Protect is not killing the pathogen that causes fire blight, but rather renders it ineffective. Dr. Yang’s approach is a unique attempt to solve a more than century old problem, severely affecting farmers in the US and globally. As a result of T3 BioScience’s applied technology, Erwinia amylovora, the fire blight pathogen, will not grow resistant to the treatment, as has happened and will likely continue with antibiotics used to fight this disease. E. amylovora has no need to fight the T3 Protect treatment. Actually, it is rather oblivious of the treatment as it inhibits its T3SS mechanism, its needle like structure that would infect the apple bloom.”

Read the full story here

[Originally posted by T3BioSciences — October 6, 2018]